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Abstract 
BACKGROUND: Diabetic foot infection is a major cause of patient disabilities and lowers limb amputations, with 
high treatment costs and hospitalisation requirements.  
AIM: Aim of this study was to evaluate surgical wound care plus antibiotic effects in the treatment of mild and 
moderate diabetic foot infections.  
METHODS: This retrospective study involved 60 patients with diabetic foot infections with or without 
osteomyelitis. The patients were categorised as group 1 mild and group 2 moderate. Both groups were treated 
using local wound debridement and the systemic administration of antibiotics. Group 1 (16) patients were treated 
with two regimens of oral antibiotics in two regimens, A (amoxicillin/clavulanate + metronidazole) and B 
(clindamycin + metronidazole), for 10-14 days. Group 2 (42) patients were treated with oral plus intravenous 
antibiotics in two regimens, A (ampicillin + cloxacillin + metronidazole) and B (lincomycin + metronidazole), for 6 
weeks. The patients followed-up with local wound care specialists for 3 months to evaluate the treatment 
outcomes (cure, improvement, or failure). 
RESULTS: Group 1 had an 80% cure rate under regimen A and a 100% cure rate under regimen B. Group 2 
regimen A patients had a 61.5% cure rate and 11.53% improved, while regimen B patients had a 68.75% cure 
rate and 12.5% improved. Failure in both regimens was 23.8% in 20 patients with osteomyelitis, while 35% were 
cured and 20% improved during the study period. 
CONCLUSION: Local surgical wound care for 3 months with antibiotic regimens for 6 weeks resulted in good 
response and cure rates, with lower costs and fewer instances of hospitalisation. Intravenous lincomycin and oral 
metronidazole achieved higher cure responses for moderate diabetic foot infections. 
 
 
 
 
 
 
Introduction 
 
Diabetic foot infection is a serious 
complication of diabetes mellitus that can cause 
morbidity and disability. It is costly to treat and can be 
life-threatening, leading to lower limb amputation, and 
may cause systemic infection and septicemia if not 
treated properly [1], [2].  
International reports indicate that 25-50% of 
diabetic patients are subject to amputations due to 
infections. In the United States, diabetic foot infections 
are associated with a higher annual rate of referral 
and hospital admission [3], [4].  
Reports highlight the negative impact of 
diabetic foot infections on patients’ lives. Diabetic foot 
infections develop due to the impact of diabetes 
mellitus on the peripheral nervous system, leading to 
the motor, sensory, and autonomic neuropathy that 
cause stress shear, foot deformity, dryness, and 
peripheral arterial atherosclerosis [5]. All these factors 
lead to foot ulcers due to minor trauma. Treatment of 
diabetic foot ulcers plays a crucial role in preventing 
infection, but recurrent ulceration and infection can 
occur. The management of diabetic foot infection 
varies according to the classification and bone 
involvement. However, outcomes generally depend on 
local wound care, surgical debridement, dressing 
changes, and pharmacological treatment [6].  
Initiating successful management includes an 
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evaluation of the patient’s medical history and health 
status, maintenance of microcirculation, wound depth, 
and infectious pathogens. In cases of mild wound 
infection, an inspection of wound depth, abscess 
drainage, evaluation of microcirculation, and culture 
sensitivity tests are important measures to choose the 
proper antibiotic treatment and avoid infection of 
adjacent tissue [7], [8]. Moderate and severe diabetic 
foot infections require more aggressive surgical 
wound debridement and drainage of abscesses with 
minor or major amputations in certain cases in 
addition to long regimens of antibiotic therapy [9], [10]. 
The proper choice of antibiotics is of great 
value to cover all the microorganisms involved. The 
antibiotics should be active against S. aureus and 
streptococci species that are frequently isolated [11]. 
Different guidelines are available for antibiotic 
selection with no fixed routes, duration, and/or 
superiority of certain regimens. However, each 
protocol depends on the severity of infection, isolated 
microorganisms, and history of previous antibiotic 
treatment [12], [13], [14]. 
The current study aimed to evaluate surgical 
wound management and antibiotic treatment 
according to the case severity of diabetic foot 
infections.  
 
 
Methods 
 
We conducted a retrospective clinical study to 
evaluate the surgical and antibiotic treatment of 
patients who presented at an orthopaedic consultation 
clinic from October 2015 to November 2016 with 
diabetic foot infections of mild and moderate severity 
according to the IDSA classification (Table 1) [2]. 
Table 1: Diabetic foot infection severity according to IDSA 
classification 
Clinical description  Severity 
Manifestations of inflammation (purulence or erythema, pain, 
tenderness, warmth, or induration); any cellulitis or erythema 
extends ≤ 2 cm around the ulcer, limited to skin or superficial 
subcutaneous tissues; no local complications or systemic 
illness 
Mild 
Infection in a patient who is systemically well and metabolically 
stable but has ≥ 2 cm; lymphangitis; spread beneath fascia; 
deep tissue abscess; gangrene; muscle, tendon, joint, or bone 
involvement 
Moderate 
Infection in a patient with systemic toxicity or metabolic 
instability. 
Sever 
 
 
Patients 
A total of 60 patients were involved in the 
current study. Their clinical data were recorded, 
including general information, history of diabetes 
mellitus, history of diabetic foot infection, history of 
previous amputation, current antibiotic therapy, and 
medications . 
Examination of the patients included general 
examination, vital signs, local examination of both feet 
including neurovascular assessment, and examination 
of the infected area(s). The patients underwent 
serological investigations, including random blood 
sugar, PCV, WBC, C-reactive protein, and ESR. 
Imaging studies included X-rays of the infected foot 
with AP and lateral views (Table 2). 
Table 2: Patient's clinical data 
Criteria All patients n = 58 
Sex ratio female\male 22\36 
Age mean ± SD 61.5 ± 10.5 
Site of infection 
 
 
Toes = 30 (58) 
Heel = 6 (58) 
Other site = 10 (58) 
Mixed (more than one site) = 12 (58) 
Patients with osteomyelitis 20 patients (58) 
History of the previous infection 46 (58) 
History of amputation 18 (58) 
Patients need partial or complete 
toe (s) amputation during wound 
debridement 
16 (58) 
 
Doppler studies of both lower limbs were 
performed to assess circulation. We then consulted an 
endocrinologist to control the patients' blood sugar 
and a vascular surgeon to evaluate their peripheral 
circulation. 
Exclusion criteria were (1) severe types of 
infection according to the IDSA classification, (2) 
severe ischemia with gangrenous lesions, and (3) 
diabetic foot ulcers with no signs of infection. 
 
Treatments  
Local wound care  
We started with wound debridement under 
local anaesthesia and drainage of abscesses (after 
obtaining wound swabs for culture and sensitivity 
testing). Some wounds required limited surgical 
resection of parts of the toe or toes followed by 
irrigation with normal saline and dressing with gauze 
soaked in 2% iodine solution. According to the 
severity, the dressings were changed 1-2 times a day. 
The patients' wounds were followed-up every 5 days, 
then every 10-14 days for 3 months after initial 
improvement. 
 
Antibiotic treatment 
Empirical antibiotic treatment was as follows: 
Group 1. For mild diabetic foot infections 
according to the IDSA, the patients in regimen A 
received 1 dose of oral amoxicillin/clavulanate every 
12 hours + 1 dose of metronidazole every 8 hours for 
10-14 days (Figure 1). The patients in regimen B who 
were allergic to penicillin or already on penicillin 
without a response were administered 1 dose of 
clindamycin every 6 hours + one dose of 
metronidazole every 8 hours for 10-14 days. 
Group 2. For the patients with moderate 
diabetic foot infection with or without osteomyelitis, 
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those in regimen A received intravenous 
ampicillin/cloxacillin + metronidazole orally for 5 days 
and then either repeated this course if the response 
was inadequate or changed to an oral regimen similar 
to group 1 regimen A for not less than 6 weeks. The 
patients in regimen B who were allergic to penicillin or 
already on penicillin without a response received 
intravenous lincomycin + oral metronidazole for 5 
days and then either repeated this course if the 
response was inadequate or changed to an oral 
regimen according to group 1 regimen B for not less 
than 6 weeks (Figure 1). 
 
Figure 1: Study design diagram 
 
Drugs 
(1) Amoxicillin/clavulanate, 1000 mg oral 
tablets (CoAmox Acino, Acino, Zurich, Switzerland). 
(2) Metronidazole, 500 mg oral tablets (Flagyl, 
Sanofi-Aventis, Gentilly, France). 
(3) Clindamycin hydrochloride, 300 mg oral 
capsules (Lanacin, Al-Mutahida, Amman, Jordan). 
(4) Ampicillin + cloxacillin, 250 mg/250 mg 
intravenous injection (LDP Torlan, Barcelona, Spain). 
(5) Lincomycin hydrochloride, 600 mg 
intravenous injection every 8 hours (Lincocin, Pfizer, 
Puurs, Belgium). 
Outcome assessment  
We classified the patients according to their 
responses to management during the follow-up 
periods, which were every 5 days in the acute stage 
(for the first 3 weeks), then every 10-14 days for the 
next 3 months. 
The responses according to Lipsky (1997) 
[15] were (1) cure: all signs and symptoms of 
inflammation, pus, and osteomyelitis had 
disappeared, and the wound had begun to heal; (2) 
improvement: incomplete abatement of the signs and 
symptoms of infection; and (3) failure: no 
improvements. 
Secondary outcomes involved adverse 
reactions to the antibiotic regimens. 
 
 
Results 
 
Overall, 58 patients were included in this 
study after the exclusion of two cases due to the 
development of adverse reactions to the medications. 
Among the patients in group 1 who received regimen 
A, eight were cured (80%) and 2 (20%) failed to 
respond and shifted to regimen B in group 1, while 6 
patients in group 1 who received regimen B (100%) 
were cured after a treatment period of 10-14 days 
(Table 3). 
Table 3: Clinical outcome of 16patients included in group1 
(mild diabetic foot infection) 
Group 1 
No.16 
Patients outcome of both regimen A, B 
of treatment 
Regimen A 
No .10 
 
Regimen B 
No.6 
Cure 
Improved 
Failed 
 
14 (16) 87.5% 
0 
2 (16) 12.5% 
shifted to G2 
8 (10) 80% 
0 
2 (10) 20% 
100% 
0 
0 
 
A total of 42 patients were included in group 
2, and 26 received regimen A; 16 patients were cured, 
3 improved, and 7 failed to respond at the end of the 
treatment period (Table 4). 
Table 4: Total clinical outcome of 42patients included in-
group2 at the end of the treatment period (moderate diabetic 
foot infection) 
Group 2 
Patients No.42 
Total clinical outcome 
of both regimen 
Regimen A 
No.26 
Regimen B 
No.16 
Cure 27 (42) 64.28% 16 (26) 61.5% 11 (16) 68.75% 
Improved 5 (42) 11.9% 3 (26) 11.53% 2 (16) 12.5% 
Failed 10 (42) 23.8% 7 (26) 26.9% 3 (16) 18.75% 
 
A total of 16 patients in group 2 received 
regimen B; 11 were cured, 2 improved, and 3 failed to 
respond at the end of the treatment period (Tables 4 
and 5). 
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Table 5: Clinical outcome of group 2 about duration of 
parenteral injection 
Group 2 
Patients 
No.42 
6 weeks regimen including 
5 days of injectable treatment 
6 weeks regimen 
including 
10 days of injectable 
treatment 
 
6 weeks regimen 
including 
15 days of injectable 
treatment 
 
A 
No. (%) 
B 
No. (%) 
A 
No. (%) 
B 
No. (%) 
A 
No. (%) 
B 
No. (%) 
Cure 12 (28.57%) 4 (9.5%) 4 (9.5%) 6 (14.28%) 0 1 (2.3%) 
Improved 2 (4.7%) 1 (2.3%) 1 (2.3%) 1 (2.3%) 0 0 
Failed 1 (2.3%) 1 (2.3%) 1 (2.3%) 0 5 (11.9%) 2 (4.7%) 
 
Secondary outcomes included diarrhoea and 
skin rash, which developed in 2 patients in group 1 
and required changes in treatment and exclusion. 
Most of the patients well tolerated the antibiotics with 
minor gastric upset that was treated with antacids. 
The results of culture and sensitivity tests in 
21 patients were mainly Gram-positive species 
including staphylococci and streptococci. Most were 
mixed infections; three patients had E. coli, and one 
had pseudomonas. 
Two patients in group 1 regimen A were 
switched to group 1 regimen B, and both were cured 
after 14 days of treatment . 
The follow-up period continued for 3 months, 
including local wound care every 10-14 days (after 
completion of the antibiotic regimens). As a result, (1) 
there was no recurrence in the cured cases; (2) 3 of 
the improved cases were cured at the end of the 
follow-up period, while 2 cases had to repeat the 
antibiotic regime; and (3) all of the failed cases 
resulted in amputation.  
 
 
Discussion 
 
Diabetes mellitus is a systemic disease 
associated with complications that lead to morbidity. 
One of these complications is diabetic foot infection 
that may end with morbidity and mortality. 
Many treatment guidelines lead to good 
clinical outcomes. All aim for higher success rates 
with less risk of amputations. 
The current study’s goal was to evaluate 
surgical and pharmacological therapy for diabetic foot 
infection of mild and moderate severity in outpatients 
both with and without osteomyelitis. We choose the 
IDSA classification, as it was more applicable to and 
representative of our cases and easily performed. 
Severe cases were excluded due to the necessity for 
hospitalisation. The included patients were treated in 
an orthopaedic consultation clinic using thorough 
wound debridement and dressing soaked in iodine to 
ensure protection from contamination. Wound 
debridement and care are very important as the initial 
step in diabetic foot infection treatment to remove all 
necrotic tissue and drain abscesses. Frequent daily 
dressing is a very effective method for controlling 
infection and reducing the need for long-term 
antibiotic administration [16], [17], [18]. 
In this study, we used inexpensive antibiotics, 
have been widely used for many years, have well-
known side effects, and can be administered to 
outpatients. Also, they include all common types of 
causative microorganisms of diabetic foot infections. 
Using these types of antibiotics leads to a success 
rate, similar to the results of recent studies including 
new generations of antibiotics that are expensive, 
require hospital admission, and necessitate similar 
treatment periods [19], [20], [21]. 
The cure rate in group 1 was 87.5%, which is 
acceptable, as the patients had no osteomyelitis and 
positive responses to the selected empirical 
antibiotics; there was good coverage of the 
microorganisms in this wound type with adequate 
penetration of the infected skin, soft tissue, and bone, 
in addition to low cost. Our results agree with those of 
De Vries [22] in a study that retrospectively evaluated 
the effectiveness of clindamycin and cephalosporin for 
the treatment of diabetic foot infection caused by 
Staphylococcus aureus and Gram-negative 
organisms, with an 87% success rate. 
Metronidazole was administered to both 
groups as it is well tolerated and provides 
antimicrobial activity against most anaerobic 
microorganisms involved in this condition and colitis 
caused by Clostridium difficile [23]. This could explain 
the low frequency of adverse reactions observed 
during the treatment period; adverse reactions 
occurred in 2 patients in the group treated with oral 
clindamycin . 
In group 2, the cure rate was 64.28% in both 
regimes, although 20 patients had osteomyelitis, 
which can affect the success rate. Nevertheless, 35% 
of the patients with osteomyelitis were cured and 20% 
improved during the antibiotic regimen, which lasted 
for 6 weeks, and none relapsed during the 3-month 
follow-up period. There was no need for 
hospitalisation and further costs (Table 6). 
Table 6: Clinical outcome about osteomyelitis involvement 
Group 2 
Patients 
with 
osteomyel
itis No.20 
 
6 weeks regimen 
including 
5 days of injectable 
treatment 
 
6 weeks regimen 
including 
10 days of 
injectable treatment 
 
6 weeks regimen 
including 
15 days of injectable 
treatment 
Total 
A 
No. (%) 
B 
No. (%) 
A 
No. (%) 
B 
No. (%) 
A 
No. (%) 
B 
No. (%) 
No. (%) 
Cure 2 (10%) 0 (0) 1 (5%) 3 (15%) 0 1 (5%) 7 (35%) 
Improved 1 (5%) 1 (5%) 1 (5%) 1 (5%) 0 0 4 (20%) 
Failed 1 (5%) 1 (5%) 1 (5%) 0 (0) 4 (20%) 2 (10%) 9 (45%) 
 
The success rate of this study was 
comparable to many others, such as that of Yadlapalli 
[24], which reviewed 58 patients with diabetic foot 
infections and osteomyelitis treated for 4-6 weeks via 
intravenous injection of ceftizoxime, 
ampicillin/sulbactam, cefoxitin, and vancomycin; 
79.3% of the patients were healed, although with a 
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different regime of antibiotics. Embil et al., [25] 
retrospectively reviewed 325 patients treated with oral 
antibiotics and oral plus intravenous antibiotics 
including metronidazole, clindamycin, 
amoxicillin/clavulanate, ciprofloxacin, and co-
trimoxazole. They found a 75.8% remission rate in the 
oral plus intravenous regimen, although patients with 
abscesses and acute osteomyelitis were excluded, 
unlike the current study. 
A review of the failed cases found that most 
were due to uncontrolled blood sugar, despite 
consultation with the endocrinologist; this was mainly 
related to the low socioeconomic status of most of the 
patients in our study. 
In conclusion, patients with diabetic foot 
infections treated with surgical debridement and 
antibiotic regimens had favourable responses and 
cure rates during the study period, with lower costs 
and hospitalisation rates. Local wound care and good 
local follow-up improved the success rate and 
reduced the duration of antibiotic treatment. Oral 
clindamycin and metronidazole have superior success 
rates in patients with mild diabetic foot infections and 
intravenous lincomycin and oral metronidazole show a 
higher cure rate among moderate diabetic foot 
infection patients with or without osteomyelitis. 
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